Production (Stage)
COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 7.16M | 7.16M | 6.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 7.16M | 7.16M | 6.22M |
| Cost of Revenue | -- | -- | 6.72M | 6.72M | 5.80M |
| Gross Profit | -- | -- | 443.00K | 443.00K | 421.00K |
| SG&A Expenses | -- | -- | 1.82M | 5.89M | 4.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 6.23M | 10.30M | 6.71M |
| Operating Income | -- | -- | 935.00K | -3.14M | -495.00K |
| Income Before Tax | -- | -- | -1.31M | -1.31M | -506.00K |
| Income Tax Expenses | -- | -- | -1.77M | -1.77M | -1.53M |
| Earnings from Continuing Operations | -- | -- | 0.46 | 0.46 | 1.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 464.00K | 464.00K | 1.03M |
| EBIT | -- | -- | 935.00K | -3.14M | -495.00K |
| EBITDA | -- | -- | 2.74M | -1.33M | 1.30M |
| EPS Basic | -- | -- | -2.83 | -2.83 | -2.65 |
| Normalized Basic EPS | -- | -- | -0.81 | -2.19 | -2.03 |
| EPS Diluted | -- | -- | -2.83 | -2.83 | -2.66 |
| Normalized Diluted EPS | -- | -- | -0.81 | -2.19 | -2.03 |
| Average Basic Shares Outstanding | -- | -- | 9.03M | 9.03M | 8.66M |
| Average Diluted Shares Outstanding | -- | -- | 9.03M | 9.03M | 8.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |